Skip to content

Reported August 5, 2025 · After market close

Revenue$58.9MBeat by $3.5M
EPS-$0.17Beat by $0.07
Revenue estimate$55.4M
EPS estimate-$0.24

Next report

Date not yet announced

Financials

Q2 2025

Income statement

See full
Revenue$58.9M+36.3%
Gross profit$40.9M+71.2%
Operating income-$25.0M+47.1%
Net income-$25.6M+44.6%
EPS (diluted)-$0.17+45.2%

Balance sheet

See full
Cash & equivalents$43.2M-27.9%
Total debt$217.9M-3.7%
Total equity$179.7M-25.6%
Total assets$496.6M-15.1%

Cash flow

See full
Operating cash flow-$12.4M+28.2%
CapEx$655.0K-62.1%
Free cash flow-$13.1M+31.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.62B+203%
Enterprise value$1.79B+156%
P/S7.9×+4.7×

Profitability

See full
Gross margin66%+11.3pp
Operating margin-59%-20.8pp
Net margin-59.1%-20.5pp
FCF margin-40.4%-13.5pp

Returns & leverage

See full
Return on equity-57.5%-7.1pp
Debt / equity1.2×+0.3×
Current ratio2.8×-1.1×

Segments

By product

See full
Service$44.4M+37.6%
Regulatory Milestone Revenue$5.5M+83.3%
Collaboration Revenue$3.9M+124%

By segment

See full
Mrd Business$49.9M+41.5%
Immune Medicine Business$8.9M+13.1%

Versus estimates

Ask the moment Adaptive Biotechnologies reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Adaptive Biotechnologies report Q2 2025 earnings?
Adaptive Biotechnologies (ADPT) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Adaptive Biotechnologies's Q2 2025 revenue and EPS?
Adaptive Biotechnologies reported revenue of $58.9M and eps of $-0.17 for Q2 2025.
Did Adaptive Biotechnologies beat estimates in Q2 2025?
Revenue beat the consensus estimate of $55.4M by $3.5M. EPS beat the consensus estimate of $-0.24 by $0.07.
How did Adaptive Biotechnologies's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 36.3% from $43.2M a year earlier and eps grew 34.6% from $-0.26.
Where can I find Adaptive Biotechnologies's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-103120) directly on SEC EDGAR. The filing index links above go to sec.gov.